C. BELLANTUONO, L. TENTONI - Vol. 9, June 2003, Issue 2
Testo Immagini Bibliografia Summary Indice
Farmaci antipsicotici e rischio di diabete:
un approccio evidence-based
Antipsychotic drugs and risk of diabetes: an evidence-based approach
1 Kooy FH. Hyperglycemia in mental disorders. Brain 1919;42:214-88.
2 Lorenz WF. Sugar tolerance in dementia praecox and other mental disorders. Arch Neurol Psychiatry 1922;8:184-96.
3 Finney GOH. Juvenile onset diabetes and schizophrenia? Lancet 1989;2:1214-5.
4 American Diabetes Association. National Standards for Diabetes Self-Management and American Diabetes Association Review Criteria. Diabetes Care 1999;22(suppl. l):S111-S114.
5 National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
6 World Health Organization Expert Committee on Diabetes Mellitus. Second report. WHO Tech Rep Ser 646, 1980.
7 http://www.who.int/ncd/dia/databases.htm.
8 Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24.
9 Kasanin J. The blood sugar curve in mental disease. Arch Neurol Psychiatry 1926;16:414-9.
10 Balter AM. Glucose tolerance curves in neuropsychiatric patients. Diabetes 1961;10:100-4.
11 Braceland FJ, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry 1945;102:108-10.
12 Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1956;29:827-8.
13 Charatan FBE, Bartiett NG. The effect of chlorpromazine ("Largactil") on glucose tolerance. J Ment Sci 1955;101:351-3.
14 Hiles BW. Hyperglycemia and glycosuria following chlorpromazine therapy. JAMA 1956;126:1651.
15 Arneson GA. Phenothiazine derivatives and glucose metabolism. J Neuropsychiatry 1964;5:181-5.
16 Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1968;124:978-82.
17 Keskiner A, El Toumi A, Bousquet T. Psychotropic drugs, diabetes, and chronic mental patients. Dis Nerv Syst 1973;14:176-81.
18 Schwarz L, Munoz R. Blood sugar levels in patients treated with chlorpromazine. Am J Psychiatry 1968;125:253-5.
19 Tabata H, Kikuoka M, Kikuoka H, Bessho H, Hirayama J, Hanabusa T, et al. Characteristics of diabetes mellitus in schizophrenic patients. J Med Assoc Thai 1987;70(suppl. 2):90-3.
20 Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996;37:68-73.
21 Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-12.
22 Lindemayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62(suppl 23):30-8.
23 Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000;157:975-81.
24 Lindenmayer JP, Smith RC, Singh A, Parker B, Chou E, Kotsaftis A. Hyperglycemia in schizophrenic patients treated with olanzapine. J Clin Psychopharmacol 2001;48:351-3.
25 Koro CE, Fedder DO, L’Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243.
26 Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997;50:1097-9.
27 Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 2002; 63:758-62.
28 Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63:920-30.
29 Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002;63:1135-9.
30 Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001;58:1172-6.
31 Cavazzoni P, Baker RW, Kwong K, et al. A retrospective cohort study diabetes mellitus end antipsychotic treatment in the United States Journal of Clinical Epidemiology 2003;56:164-70.
32 Meyer JM. A retrospecitve comparison of weight, lipid and glucose changes between risperidone- and olanzapine- treated impatients: metabolic outcomes after 4 year. J Clin Psychiatry 2002;63:425-33.
33 Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatement of schizophrenia. Am J Psychiatry 2002;159:561-6.
34 Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856-65.
35 Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59:294-9.
36 Melkersson KI, Hulting AL, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry. 1999;783-91.
37 Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000;61:742-9.
38 Biswasl PN, Wilton LV, Pearcel GL, Freemantle S, Shakir SA. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol 2001;15:265-71.
39 American diabetes Association. ADA Website: Impact of diabetes. Aviable at: http://www.diabetes.org:80/main/application/commercewf?origin=*.jsp&event=link(B1_1). Accessed December 10, 2001.
40 Imperadore G, Balestrieri M, Bellantuono C. Il trattamento farmacologico della schizofrenia. In: Bellantuono C, Balestrieri M, eds. Trattato di Psicofarmacologia Clinica. Roma: Il Pensiero Scientifico Editore 2003.
41 Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-9.
42 Allison DB, et al. Presented at: 2001 International Congress of Schizophrenia Research, Vancouver, British Columbia.
43 Glick ID, et al. Presented at: 2001 Annual Meeting of the American Psychiatric Association, New Orleans, Louisiana.
44 Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol. 2003;56(2):164-70.